Clinical Trial

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Name: SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors — clinical trial record (NCT07646626)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.

Trial Details

NCT Number	NCT07646626
Lead Sponsor	Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions	Locally Advanced (Unresectable) or Metastatic Solid Tumors
Enrollment	150 participants
Start Date	2026-07-17
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-28